source
- Sarepta appoints former AbbVie executive Michael Severino as new CEO to drive turnaroundSarepta Therapeutics announced that Michael Severino will become its chief executive officer on July 28, succeeding Doug Ingram who plans to retire. Severino brings more than two decades of experi…
- Apnimed targets up to $160 million IPO to fund launch of Oxnimbi, its oral sleep apnea pillApnimed, a Massachusetts biotech, filed with the SEC indicating it will seek an IPO of up to $160 million to finance the commercial launch of its oral obstructive sleep apnea therapy, Oxnimbi (AD10…